acf/google-ad-placement

Never miss a trade again with the fastest news alerts in the world!
 This headline only article is a sample of real-time intelligence
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Benzinga Pro</a> traders use to win in the markets everyday.
 Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters?
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Join 10,000+ serious traders in the Benzinga Pro community!</a>

Biotech

News

Health Care

General

The restructuring is expected to result in a 20% reduction in cash operating expenses when fully realized in Q3 2025, compared to the prior reporting period.The Company's cash flow break-even target assumes scaling to

Bluebird Bio Is Implementing A Restructuring Intended To Optimize Its Cost Structure And Enable Quarterly Cash Flow Break-even In 2H Of 2025, Including Reduction In Workforce Of Approximately 25% - bluebird bio (NASDAQ:BLUE)

Benzinga Newsdesk

bluebird bio

BLUE

Bluebird Bio Is Implementing A Restructuring Intended To Optimize Its Cost Structure And Enable Quarterly Cash Flow Break-even In 2H Of 2025, Including Reduction In Workforce Of Approximately 25%

Comments